TLSI Form 4: Chief of Research awarded RSUs and options

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. (TLSI) reported an equity compensation grant to its Chief of Research. On November 24, 2025, the officer received 40,000 shares of common stock as a restricted stock unit award at a price of $0, increasing beneficial ownership to 166,599 common shares held directly. These RSUs vest in four equal annual installments starting November 24, 2025, conditioned on continued employment.

The officer was also granted an employee stock option to purchase 80,000 shares of common stock at an exercise price of $5.55 per share, expiring on November 23, 2035. One-fourth of the option vests on November 24, 2026, with the remaining portion vesting monthly thereafter, also subject to continued employment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cox Bryan F.

(Last) (First) (Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER CO 80031

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief of Research

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/24/2025		A		40,000(1)	A	$0	166,599	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$5.55	11/24/2025		A		80,000		(2)	11/23/2035	Common Stock	80,000	$0	261,954	D

Explanation of Responses:

1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on November 24, 2025, subject to continued employment through the respective vesting date.

2. One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of November 24, 2025 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to continued employment through the respective vesting date.

Remarks:

	/s/ Mary Szela, Attorney-in-Fact	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards were reported for TriSalus Life Sciences (TLSI) in this Form 4?

The filing reports a grant of 40,000 restricted stock units payable in TriSalus Life Sciences common stock and an employee stock option for 80,000 shares at an exercise price of $5.55 per share.

Who received the equity awards in the TLSI Form 4 filing?

The awards were granted to an officer of TriSalus Life Sciences who serves as the company’s Chief of Research and is a reporting person under Section 16.

How do the 40,000 TLSI restricted stock units vest?

The 40,000 RSUs vest in four equal annual installments beginning on November 24, 2025, and each installment requires the officer to remain employed through the applicable vesting date.

What are the key terms of the 80,000-share stock option reported by TLSI?

The employee stock option covers 80,000 shares of TriSalus Life Sciences common stock at an exercise price of $5.55 per share and expires on November 23, 2035.

How does the 80,000-share TLSI stock option vest over time?

For the stock option, one-fourth of the shares vest on November 24, 2026, and 1/36th of the remaining shares vest monthly thereafter on the same day, subject to continued employment through each vesting date.

What is the officer’s TLSI common stock ownership after these transactions?

After the reported grant of restricted stock units, the officer beneficially owns 166,599 shares of TriSalus Life Sciences common stock directly.